Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.36 |
| ▸ | RAD52 | P43351 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790181 | 0.88 | PNMT (0.40) | PNMTALDH1A1GRIA1GRIA2GRIA3 | |
| SCHEMBL6790350 | 0.80 | GRIA1 (0.51) | GAAKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL6783643 | 0.79 | ADRA2A (0.37) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL7980429 | 0.79 | KMT2A (0.51) | PNMTGAAKDM4EMEN1ALDH1A1 | |
| SCHEMBL7980176 | 0.76 | GAA (0.47) | GAAKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL5130512 | 0.76 | PNMT (0.42) | PNMTGAAKDM4EMEN1ALDH1A1 | |
| SCHEMBL6780229 | 0.75 | GRIA1 (0.51) | GAAALDH1A1MAPTGRIA1GRIA2 | |
| SCHEMBL7980579 | 0.74 | SIGMAR1 (0.47) | PNMT | |
| SCHEMBL8188636 | 0.74 | KDM4E (0.45) | KDM4EALDH1A1CASP1 | |
| SCHEMBL7970103 | 0.74 | MEN1 (0.50) | PNMTGAAKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114422-A1 | NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-06-19 | — | — | US | claimed |
| EP-0664807-B1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER LAMBERT CO (US) | 1997-09-10 | — | — | EP | claimed |
| EP-0664807-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS. | WARNER LAMBERT CO (US) | 1995-08-02 | — | — | EP | claimed |
| WO-1994009000-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | claimed |
| US-6703391-B2 | THROMBOSIS, BRAIN DISORDERS, CARDIOVASCULAR DISORDERS, ALZHEIMER'S DISEASE, HUNTINGTON DISEASES | NEUROSEARCH A/S (DK) | 2004-03-09 | — | — | US | disclosed |
| US-20030114422-A1 | NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-06-19 | — | — | US | disclosed |
| EP-0664807-B1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER LAMBERT CO (US) | 1997-09-10 | — | — | EP | disclosed |
| EP-0664807-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS. | WARNER LAMBERT CO (US) | 1995-08-02 | — | — | EP | disclosed |
| EP-0452987-B1 | Isoindoline derivatives | BANYU PHARMA CO LTD (JP) | 1995-03-01 | — | — | EP | disclosed |
| WO-1994009000-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114422-A1 | NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE | CHRNA3, CHRNA7, CHRNB3 | PNMT 2087/4885GAA 2937/4885KDM4E 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.